Money Times Talk

---

Get the latest Indian stock / share market highlights, BSE/NSE stock news, business research reports & details - updated daily by Money Times.

---

February 01, 2024

• ➢ A market veteran is hopeful of a positive outlook of the Union Budget. He expects it to be favorable and
• anticipates a positive market breadth leading up to the elections. He believes that fiscal deficit is likely to be lower
• than estimated and supported by concrete facts and figures. The sectors to look for are Auto, Auto Ancillaries,
• Chemicals, Defense, Infrastructure, Mid cap IT, Power, Print Media, Real Estate, Railways and selective banks.
• Important turning dates in the market are 30th & 31st January and in February 1st, 8th, 16th, 26th and 28th
• .
• ➢ In our 4th Nov MTTs, Cosmic CRF recommended at Rs.263 touched Rs.1056.
• ➢ In our 2nd Dec MTTs, S J Logistic recommended at Rs.190 touched Rs.245.
• ➢ In our 18th Dec MTTs, BMW recommended at Rs.56 touched Rs. 86.
• ➢ In our 25th Dec MTTs, Electrosteel recommended at Rs.113 touched Rs.161 and Man Industries recommended
• at Rs.251 touched Rs.404. Book partial profits at every rise.
• ➢ In our 13th Jan MTTs, Systango recommended at Rs.275 touched Rs.320.
• ➢ In our 21st Jan MTTs, Dhanalaxmi Roto recommended at Rs.186 touched Rs.224, Walchandnagar’s Peoplefirst
• was recommended at Rs.189 touched Rs.226 and Goa Carbon recommended at Rs.721 touched Rs.799. HFCL
• recommended at Rs.99 touched Rs.109, IRB Infra recommended at Rs.49 touched Rs.51, PSU GIPCL
• recommended at Rs.194.50 touched Rs.202, Vakrangee recommended at Rs.21 touched Rs.23.10, Jain Irrigation
• recommended at Rs.63.85 touched Rs.65, Indotech transformers recommended at Rs.874 touched Rs.922 and
• Fredun Pharma recommended at Rs.848 touched Rs.911. All these look good for the short term.
• ➢ Natco Pharma invested $2 mn in Cellogen Therapeutics Pvt. Ltd., focusing on cell and gene therapy for various
• medical conditions. It's vertical integrated exports to 50 countries is 536% higher Q2 EPS of Rs.20.6 and 112%
• higher H1 EPS of Rs.43.9 which may lead to FY24 EPS of Rs.80+. Buy.